• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants

tetano

Editor, Senior Moderator
Front Immunol


. 2025 May 28:16:1597417.
doi: 10.3389/fimmu.2025.1597417. eCollection 2025. Heterologous prime-boost vaccination drives stromal activation and adaptive immunity against SARS-CoV-2 variants

Ji Hyang Jeon[SUP] #[/SUP][SUP] 1 2 [/SUP], Seongryong Kim[SUP] #[/SUP][SUP] 3 [/SUP], Seo-Yeon Kim[SUP] 1 [/SUP], Kwang-Soo Shin[SUP] 4 [/SUP], Bongju Park[SUP] 4 [/SUP], Soojeong Chang[SUP] 4 [/SUP], Chang-Yuil Kang[SUP] 4 [/SUP], You-Jin Kim[SUP] 1 [/SUP], Jong-Eun Park[SUP] 3 [/SUP], Sungsu Youk[SUP] 2 5 [/SUP], Dokeun Kim[SUP] 6 [/SUP], Jinah Yeo[SUP] 1 [/SUP]



Affiliations
Abstract

Heterologous vaccination strategies have shown superior efficacy over homologous regimens in clinical studies, but the underlying immunological mechanisms remain incompletely understood. Using a mouse model, we investigated the immune responses induced by heterologous prime-boost vaccination with adenoviral and mRNA vaccines. Heterologous vaccination (adenoviral prime, mRNA boost) elicited higher neutralizing antibody titers and stronger CD8[SUP]+[/SUP] T cell responses against Delta and Omicron-BA.5 variants compared to homologous regimens. Single-cell transcriptomic analysis of injection-site tissues revealed that adenoviral priming induced minimal changes in cellular composition but established a pre-conditioned innate immune environment. This effect was further amplified upon mRNA boosting, particularly through fibroblast-driven chemokine responses that promoted immune cell recruitment. These findings suggest that adenoviral priming enhances local immune activation upon boosting, contributing to the heightened adaptive immune response observed in heterologous vaccination. This study provides mechanistic insights into the immunological effects of heterologous prime-boost strategies against SARS-CoV-2 variants.

Keywords: COVID-19; adenoviral vaccine; cross immunity; heterologous vaccination; immune response; mRNA vaccine; single cell transcriptional analysis.

 
Back
Top Bottom